P/E ratio for Ligand Pharmaceuticals (LGND)

P/E ratio history for Ligand Pharmaceuticals from 2001 to 2026

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	41.3	30.89%	🇺🇸 USA
Pfizer PFE	40.5	28.28%	🇺🇸 USA
Eli Lilly LLY	45.9	45.47%	🇺🇸 USA
Amgen AMGN	29.5	-6.59%	🇺🇸 USA
Baxter BAX	-18.8	-159.51%	🇺🇸 USA
Merck MRK	151	379.60%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.2	-55.03%	🇺🇸 USA
GSK plc GSK	17.8	-43.71%	🇬🇧 UK
Spectrum Pharmaceuticals SPPI	-2.86	-109.06%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.